[
  {
    "ts": null,
    "headline": "INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma",
    "summary": "Incyte's phase III study of Monjuvi combo for first-line DLBCL treatment met primary and key secondary goals, paving the way for a 2026 FDA filing.",
    "url": "https://finnhub.io/api/news?id=904c717311e7b85ff59f7da15393922af3c1ebdee7932d54d089e066d817a346",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767712740,
      "headline": "INCY's Phase III Monjuvi Study Meets Key Goals in First-Line Lymphoma",
      "id": 138002097,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Incyte's phase III study of Monjuvi combo for first-line DLBCL treatment met primary and key secondary goals, paving the way for a 2026 FDA filing.",
      "url": "https://finnhub.io/api/news?id=904c717311e7b85ff59f7da15393922af3c1ebdee7932d54d089e066d817a346"
    }
  },
  {
    "ts": null,
    "headline": "Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names",
    "summary": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.",
    "url": "https://finnhub.io/api/news?id=2d082e60dc364035030ab16de4a62287bb23b2b56a2bdbf6abb994126329ca74",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767708005,
      "headline": "Looking for Stocks with Positive Earnings Momentum? Check Out These 2 Medical Names",
      "id": 138002098,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.",
      "url": "https://finnhub.io/api/news?id=2d082e60dc364035030ab16de4a62287bb23b2b56a2bdbf6abb994126329ca74"
    }
  },
  {
    "ts": null,
    "headline": "Is Bristol-Myers Squibb Company's (NYSE:BMY) 33% ROE Better Than Average?",
    "summary": "While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...",
    "url": "https://finnhub.io/api/news?id=dd4e2564eae47cfcbfde8771e1e04aa022c0337f2111a2b67da9ef9fa0edc8da",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767704415,
      "headline": "Is Bristol-Myers Squibb Company's (NYSE:BMY) 33% ROE Better Than Average?",
      "id": 138000203,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...",
      "url": "https://finnhub.io/api/news?id=dd4e2564eae47cfcbfde8771e1e04aa022c0337f2111a2b67da9ef9fa0edc8da"
    }
  },
  {
    "ts": null,
    "headline": "Big Pharma Has More Going for It Than Obesity Drugs",
    "summary": "Pharmaceutical companies are getting a fresh look for a range of drugs in development, plus a regulatory reprieve.",
    "url": "https://finnhub.io/api/news?id=a61b717e4912048699622837b155b7181980706cef9754ab377060d2b9aba00a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767695400,
      "headline": "Big Pharma Has More Going for It Than Obesity Drugs",
      "id": 137999357,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Pharmaceutical companies are getting a fresh look for a range of drugs in development, plus a regulatory reprieve.",
      "url": "https://finnhub.io/api/news?id=a61b717e4912048699622837b155b7181980706cef9754ab377060d2b9aba00a"
    }
  }
]